You are here

biosimilars

Why haven't biosimilars gained ground in the U.S.?

Medical Marketing and Media

Wed, 10/25/17 - 10:44 pm

Sanofi sues Mylan over Lantus patents, seeking to defend its top-selling drug

Fierce Pharma

Wed, 10/25/17 - 11:58 am

Sandoz raises questions with FDA draft guidance on statistical approaches for biosimilars

Endpoints

Wed, 10/25/17 - 10:59 am

Biosimilars could save US $150B over next decade

Biopharma Dive

Tue, 10/24/17 - 10:10 am

FDA Taking New Steps to Better Inform Physicians about Biosimilars Through Education about these Potentially Cost-Saving Options

FDA Voice

Mon, 10/23/17 - 09:53 pm

Good quarter for Roche, but competition by biosimilars concerns investors

GoinPharma

Mon, 10/23/17 - 11:27 am

Will FDA Add Suffixes to Approved Biologics' Names?

RAPS.org

Sat, 10/21/17 - 09:46 pm

Roche feeling first effects of biosimilar Rituxan

Biopharma Dive

Thu, 10/19/17 - 06:06 pm

J&J's Remicade stands firm against biosim competition in Q3

Fierce Pharma

Tue, 10/17/17 - 08:21 pm

Mylan and Biocon biosimilar of Amgen’s Neulasta hit with manufacturing-related CRL

Fierce Pharma

Tue, 10/10/17 - 10:18 am

[video+transcript]Is This How Drugmakers Will Kill Biosimilars?

Motley Fool

Tue, 10/3/17 - 11:40 am

Abbvie, Amgen Deal on Humira Biosimilars Likely to Cost CMS More Than $1B

RAPS.org

Mon, 10/2/17 - 11:18 am

How Good Is AbbVie's Humira Deal With Amgen?

Motley Fool

Fri, 09/29/17 - 10:06 am

Under Amgen and AbbVie agreement, rival drug to AbbVie's Humira expected to launch in 2023

Marketwatch

Thu, 09/28/17 - 09:50 am

Amgen targets China in cancer biosimilar development deal with Simcere

Fierce Pharma

Thu, 09/28/17 - 09:43 am

drug development

Pfizer is falling short in a competitive market, Johnson & Johnson says as it hits back at Remicade biosimilar suit

Fierce Pharma

Tue, 09/26/17 - 09:39 pm

This squabble between two big drugmakers could have major implications for the U.S. health care system

Marketwatch

Thu, 09/21/17 - 08:36 am

Pfizer files US lawsuit against Johnson & Johnson over "anticompetitive" practices related to Remicade biosimilar

First Word Pharma

Wed, 09/20/17 - 11:03 am

Remicade: A Case Study in How U.S. Pricing and Reimbursement Curb Adoption of Biosimilars

Drug Channels

Wed, 09/20/17 - 09:05 am

FDA Clears Biotech Drug Copycats, But Buying Them Isn’t So Easy

Bloomberg

Mon, 09/18/17 - 09:41 am

Pages